Who are Miacalcin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Osteobios, Zavzpret, Qulipta, Nurtec Odt, Vyepti, Ubrelvy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/calcitonin-salmon-synthetic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Miacalcin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Miacalcin (calcitonin (salmon synthetic)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcitonin [EPC]. Area: Hematology.

marketed Calcitonin [EPC] calcitonin receptors Hematology Live · refreshed every 30 min

Target snapshot

Miacalcin (calcitonin (salmon synthetic)) — Sanofi. Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Miacalcin TARGET	calcitonin (salmon synthetic)	Sanofi	marketed	Calcitonin [EPC]	calcitonin receptors	1978-01-01
Osteobios	CALCITONIN	Sanofi Aventis Us	marketed	Calcitonin [EPC]	calcitonin receptor	2025-01-01
Zavzpret	Zavegepant Hydrochloride	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	Calcitonin gene-related peptide type 1 receptor	2023-01-01
Qulipta	ATOGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2021-01-01
Nurtec Odt	rimegepant	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	calcitonin gene-related peptide receptor	2020-01-01
Vyepti	EPTINEZUMAB	Lundbeck Seattle BioPharmaceuticals, Inc.	marketed	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1	2020-01-01
Ubrelvy	UBROGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcitonin [EPC] class)

Sanofi · 1 drug in this class
Sanofi Aventis Us · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miacalcin — Competitive Intelligence Brief. https://druglandscape.com/ci/calcitonin-salmon-synthetic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab